Tourmaline Bio/$TRML
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tourmaline Bio
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Ticker
$TRML
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
74
ISIN
US89157D1054
Website
Tourmaline Bio Metrics
BasicAdvanced
$424M
-
-$3.22
-
-
Price and volume
Market cap
$424M
52-week high
$28.08
52-week low
$11.56
Average daily volume
336K
Financial strength
Current ratio
33.868
Quick ratio
32.709
Total debt to equity
0.07
Management effectiveness
Return on assets (TTM)
-19.03%
Return on equity (TTM)
-26.14%
Valuation
Price to book
1.52
Price to tangible book (TTM)
1.52
Price to free cash flow (TTM)
-5.059
Growth
Earnings per share change (TTM)
-29.23%
What the Analysts think about Tourmaline Bio
Analyst ratings (Buy, Hold, Sell) for Tourmaline Bio stock.
Tourmaline Bio Financial Performance
Revenues and expenses
Tourmaline Bio Earnings Performance
Company profitability
Tourmaline Bio News
AllArticlesVideos
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
Seeking Alpha·1 week ago
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
GlobeNewsWire·2 weeks ago
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tourmaline Bio stock?
Tourmaline Bio (TRML) has a market cap of $424M as of May 30, 2025.
What is the P/E ratio for Tourmaline Bio stock?
The price to earnings (P/E) ratio for Tourmaline Bio (TRML) stock is 0 as of May 30, 2025.
Does Tourmaline Bio stock pay dividends?
No, Tourmaline Bio (TRML) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Tourmaline Bio dividend payment date?
Tourmaline Bio (TRML) stock does not pay dividends to its shareholders.
What is the beta indicator for Tourmaline Bio?
Tourmaline Bio (TRML) does not currently have a Beta indicator.